Celiac disease and bone

Abstract Celiac disease (CD) is an autoimmune disorder characterized by small intestinal inflammation triggered by gluten ingestion in genetically-predisposed individuals. A frequent extra-intestinal manifestation of CD is metabolic bone disease which contributes to an increased risk of fracture. Th...

Full description

Bibliographic Details
Main Authors: Ananya V. Kondapalli, Marcella Donovan Walker
Format: Article
Language:English
Published: Brazilian Society of Endocrinology and Metabolism 2022-12-01
Series:Archives of Endocrinology and Metabolism
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972022000500756&tlng=en
_version_ 1811314261660532736
author Ananya V. Kondapalli
Marcella Donovan Walker
author_facet Ananya V. Kondapalli
Marcella Donovan Walker
author_sort Ananya V. Kondapalli
collection DOAJ
description Abstract Celiac disease (CD) is an autoimmune disorder characterized by small intestinal inflammation triggered by gluten ingestion in genetically-predisposed individuals. A frequent extra-intestinal manifestation of CD is metabolic bone disease which contributes to an increased risk of fracture. The mechanisms underlying bone disease in CD remain incompletely understood, but multiple processes have been proposed including (1) malabsorption of calcium and vitamin D leading to secondary hyperparathyroidism and increased skeletal resorption, (2) pro-inflammatory cytokines altering the osteoprotegerin and receptor activator of nuclear kappa-B ligand ratio favoring osteoclastogenesis, (3) hypogonadism, and (4) low weight and malnutrition. Most studies show reduced bone mineral density in patients with CD. Bone microarchitecture is also deteriorated leading to reduced whole bone stiffness. Many, but not all investigations, have shown an increased risk of fracture associated with CD. The main stay of therapy for CD is maintaining a gluten-free diet. Improvement in bone mineral density with adherence to a gluten-free diet has been well-established. Bone mineral density remains lower, however, compared to controls and increased fracture risk can persist. There is no consensus on the timing of dual-energy x-ray absorptiometry for bone mineral density assessment in patients with CD. Routine screening for CD in patients with osteoporosis is not recommended. Little data are available on the use or efficacy of prescription osteoporosis therapeutics in patients with CD. Studies are needed to develop standardized guidelines for screening and treatment of metabolic bone disease in patients with CD to identify those who may need early intervention with prescription osteoporosis therapy. Arch Endocrinol Metab. 2022;66(5):756-64
first_indexed 2024-04-13T11:08:40Z
format Article
id doaj.art-2ff45cdb01d346518c87d5af127a232b
institution Directory Open Access Journal
issn 2359-4292
language English
last_indexed 2024-04-13T11:08:40Z
publishDate 2022-12-01
publisher Brazilian Society of Endocrinology and Metabolism
record_format Article
series Archives of Endocrinology and Metabolism
spelling doaj.art-2ff45cdb01d346518c87d5af127a232b2022-12-22T02:49:12ZengBrazilian Society of Endocrinology and MetabolismArchives of Endocrinology and Metabolism2359-42922022-12-0166575676410.20945/2359-3997000000561Celiac disease and boneAnanya V. Kondapallihttps://orcid.org/0000-0002-8952-3208Marcella Donovan Walkerhttps://orcid.org/0000-0002-7205-6527Abstract Celiac disease (CD) is an autoimmune disorder characterized by small intestinal inflammation triggered by gluten ingestion in genetically-predisposed individuals. A frequent extra-intestinal manifestation of CD is metabolic bone disease which contributes to an increased risk of fracture. The mechanisms underlying bone disease in CD remain incompletely understood, but multiple processes have been proposed including (1) malabsorption of calcium and vitamin D leading to secondary hyperparathyroidism and increased skeletal resorption, (2) pro-inflammatory cytokines altering the osteoprotegerin and receptor activator of nuclear kappa-B ligand ratio favoring osteoclastogenesis, (3) hypogonadism, and (4) low weight and malnutrition. Most studies show reduced bone mineral density in patients with CD. Bone microarchitecture is also deteriorated leading to reduced whole bone stiffness. Many, but not all investigations, have shown an increased risk of fracture associated with CD. The main stay of therapy for CD is maintaining a gluten-free diet. Improvement in bone mineral density with adherence to a gluten-free diet has been well-established. Bone mineral density remains lower, however, compared to controls and increased fracture risk can persist. There is no consensus on the timing of dual-energy x-ray absorptiometry for bone mineral density assessment in patients with CD. Routine screening for CD in patients with osteoporosis is not recommended. Little data are available on the use or efficacy of prescription osteoporosis therapeutics in patients with CD. Studies are needed to develop standardized guidelines for screening and treatment of metabolic bone disease in patients with CD to identify those who may need early intervention with prescription osteoporosis therapy. Arch Endocrinol Metab. 2022;66(5):756-64http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972022000500756&tlng=enMicroarchitectureglutenfracturebone densityinflammation
spellingShingle Ananya V. Kondapalli
Marcella Donovan Walker
Celiac disease and bone
Archives of Endocrinology and Metabolism
Microarchitecture
gluten
fracture
bone density
inflammation
title Celiac disease and bone
title_full Celiac disease and bone
title_fullStr Celiac disease and bone
title_full_unstemmed Celiac disease and bone
title_short Celiac disease and bone
title_sort celiac disease and bone
topic Microarchitecture
gluten
fracture
bone density
inflammation
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972022000500756&tlng=en
work_keys_str_mv AT ananyavkondapalli celiacdiseaseandbone
AT marcelladonovanwalker celiacdiseaseandbone